Trials 17 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04500418 Comparator | Aug 2020 → Jul 2021 | COVID-19 | Charite University, Berlin, Germany | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04593940 Comparator | Oct 2020 → Jan 2022 | COVID-19 | Daniel Benjamin | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cenicriviroc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04593940 ↗ |
| Known as | Cenicriviroc mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110727 ↗ |
| Known as | Cenicriviroc Mesylate | “The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission...” NCT05630885 ↗1“Arm A: Cenicriviroc Mesylate (CVC)” NCT04334915 ↗ |
| Known as | CVC | “A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate...” NCT02342067 ↗8“This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC).” NCT02653625 ↗ “Cenicriviroc (CVC), a dual-CCR2/CCR5 antagonist, has potent anti-inflammatory and antifibrotic activity in animal models” PMID 26944023 ↗ Mar 2016 “Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.” NCT02330549 ↗ “Cenicriviroc (CVC), an oral, once-daily C-C chemokine receptor types 5 and 2 antagonist” PMID 26636929 ↗ Mar 2016 “Arm A: Cenicriviroc Mesylate (CVC)” NCT04334915 ↗ “Cenicriviroc (CVC) 150 mg” NCT03059446 ↗ “Cenicriviroc (CVC)” NCT04500418 ↗ |
| Known as | TAK-652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110727 ↗ |
| Known as | TBR 652 | “A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral...” NCT01092104 ↗ |
| Action | Inhibit | “TBR-652, a CCR5/CCR2 antagonist” PMID 21317794 ↗ Jun 2011 |
| Modality | Small molecule | — CHEMBL2110727 ↗ |
| Route | Oral | “TBR-652 monotherapy given once daily orally for 10 days” PMID 21486960 ↗ Apr 2011 |
| Target | CCR2 | “TBR-652, a CCR5/CCR2 antagonist” PMID 21317794 ↗ Jun 2011 |
| Target | CCR5 | “TBR-652, a CCR5/CCR2 antagonist” PMID 21317794 ↗ Jun 2011 |